In 2001 a team of the University-Children’s Hospital Zurich led by Professor Reichmann pursued the vision of bio-engineering personalized dermo-epidermal skin grafts, using patients’ own cells. One of the developed products, denovoSkin, is the result of fifteen years of research. A first-in-man safety study was completed with denovoSkin with very promising results. denovoSkin has obtained Orphan Drug Designation for a treatment of burns (by Swissmedic, EMA, and FDA). With the support of the regenerative medicine technology platform of Wyss Zurich the team will now proceed with product development, testing denovoSkin’s efficacy in pivotal phase II multicentric studies and prepare for market authorization in terms of regulatory and reimbursement activities.
Download denovoSkin fact sheet
PROJECT PARTNERS
Tissue Biology Research Unit, University Children’s Hospital Zurich
SkyCell
University Children’s Hospital
Dutch Burn Center
VUMC Amsterdam
University Hospital Zurich
University Hospital Birmingham
Voisin Life Science Consulting
Team
